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Summary
Pneumocystis carinii pneumonia is a leading cause of morbidity and mortality in patients with
the acquired immunodeficiency syndrome (AIDS) . Much remains unknown about the basic biology
ofP . carinii and studies of this infection have been hampered by the lack of cultivation methods .
We developed a sensitive and specific assay for P . carinii by utilizing DNA amplification of the
P . carinii dihydrofolate reductase (DHFR) gene. By this method, P . carinii DNA was detected
in the lungs of rats with experimentally induced P . carinii pneumonia 2 wk before the onset
of histopathological changes.DNA amplification analysis of serum demonstrated that by 10 wk
ofcorticosteroid treatment, 12 of 12 (100%) infected rats had circulating DHFR DNA . P . carinii
DHFRDNA also was detected in the serum ofpatients withAIDS and activeP . carinii pneumonia
(12 of 14 sera collected prospectively) . Patients with advanced AIDS but without a history of
P . carinii pneumonia were negative by this assay (0 of 6 sera examined) . Serum polymerase chain
reaction may facilitate investigations into the natural history and epidemiology ofP . carinii infection,
provide insight into the pathogenesis of parasite dissemination, and offer a useful, noninvasive
diagnostic test for the detection of human pneumocystosis .
M
ore than 60% of patients withAIDS developP . carinii
pneumonia at some point during their illness and many
develop recurrent episodes (1, 2) . Although Pneumocystis carinii
was identified as a cause of pneumonia in immunocom-
promised patients over 30 yr ago, little is known about the
natural history and transmissibility ofP . carinii because ofthe
lack of reliable isolation and culture techniques (3-5) . Presently,
the diagnosis ofP . carinii pneumonia relies on the direct mi-
croscopic visualization of organisms present in respiratory
specimens . This often requires invasive procedures such as
fiberoptic bronchoscopy or occasionally, open lung biopsy .
DNA amplification by thePCR offers a sensitive and specific
means ofidentifying diverse organisms which may be present
in biological samples (6) . In the case ofP . carinii, amplification
of ribosomal RNA genes has shown promise in increasing
the sensitivity of sputum and bronchoalveolar lavage fluid
examination (7) . In the present study, we developed a sensi-
tiveDNA amplification assay forP . carinii to begin to address
Portions of this paper were presented at the 44th Annual Meeting of the
Society of Protozoologists in Bozeman, Montana (June 1991) .
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a variety of questions concerning the pathophysiology and
natural history ofP . carinii infection. We designed this assay
to amplify the unique P . carinii dihydrofolate reductase
(DHFR)t gene (8) . By combining PCR with Southern hy-
bridization, as little as 10 fg DNA (or an average of one haploid
genome) was detected .
This assay was applied to the study of experimentally in-
duced rat pneumocystosis and to specimens obtained from
human patients withP . carinii pneumonia . In the experimental
rat model of pneumocystosis, DNA amplification detected
P . carinii in infected lungs 2 wk before the onset of histolog-
ical changes. P . cariniiDHFRDNA also was present in human
bronchoalveolar lavage fluid specimens obtained from patients
with P . carinii pneumonia . It is significant that the serum
ofexperimental animals as well as patients withP . carinii pneu-
monia contained readily detectable amounts ofP . cariniiDNA .
Serum PCR may provide insight into several aspects of the
natural history ofP . carinii infection, such as parasite latency
1 Abbreviations used in this paper . BAL, bronchoalveolar lavage; DHFR,
dihydrofolate reductase.
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human infection .
Materials and Methods
DNA Preparation .
￿
P . cariniiDNA was purified from P . carinii
obtained from infected rats . Infection was established in female
Sprague-Dawley rats (6-wk-old) which were immunosuppressed
with twice weekly injections of hydrocortisone (25 mg) and ad-
ministered alow protein (8%) diet (ICN Pharmaceuticals, Cleve-
land, OH) (9) . Animal studies were conducted in accordance with
established animal welfare guidelines. Infection in all treated animals
wasconfirmedby Giemsa stain of touch preps obtained from whole
lung tissue after 11 wk of corticosteroid treatment. Lung tissue
also was examined histologically with hematoxylin and eosin,
methenamine silver, and GramWeigert stains (5) . Some sections
also were studied by the avidin-biotin immunoperoxidase method
for the 3F6 monoclonal anti-P . carinii antibody (10) . P . carinii
trophozoites were isolated from rat lungs as previously described
(11) and purified by layering on iso-osmotic Percoll-sucrose gra-
dients (initial density 1.05 g/ml) andcentrifuging at 25,000g for
25 min . Visible P . carinii organisms were removed andjudged to
be >95% pure after histological staining. P . carinii genomicDNA
wasprepared by suspending organisms in 2ml of 10 mM Tris buffer
(pH8.0) containing 1mMEDTA . SDS (0.2% final concentration)
then wasadded, followed by ribonuclease (0 .5 mg/ml). After incu-
bation at 37° for 30 min, NaCl and proteinase Kwere added (final
concentration0.7 M and 1 mg/ml, respectively) and the solution
was incubated at 37° for 1 h .DNAwas extractedwith phenol/chlo-
roform and precipitated with ethanol.
DNAAmplificationand Detection .
￿
The 5' sense primer is : CTG
CAAAATCCTTGGATCAT (nucleotides 324-344 of theDHFR
coding region) andthe 3' antisense primer is : CTT TAGTACCAA
CCC AAG AT (nucleotides 577-597) . For DNA amplification,
5 Al of template DNA was added to 90 Al of a reaction mixture
containing 10 mM Tris buffer (pH 8.3), 50 mM KCI, 1.5 mM
MgC1 2 , 0.001% gelatin, 0.2 mM each of dATP, dCTP, dGTP, and
dTTP, and 1 AM each of the oligonucleotide primers . Taq poly-
merase was present at a final concentration of 0.026 U/pl . After
an initial 2-min denaturation step, each cycle consisted of 1 min
denaturation at 92°, 1 min annealing at 55°, and 1 min polymer-
ization at 72° . Samples were amplified for 45 cycles . 10 A,1 of reac-
tion products were electrophoresed in 2% agarose gels containing
89 mM Tris-borate, 89mMboric acid, 2mM EDTA,and100ng/ml
of ethidium bromide . Standard protocols to minimize DNA con-
tamination were followed, including intra-assay negative controls
andhandling DNA standards in a separate workplace (12) . Positive
specimenswere extracted, amplified, electrophoresed, and hybrid-
ized at least twice by two operators working with independent
reagents .
The sequence of theDHFR gene oligonucleotide probe is : 5'
GAT AGA ATT ATG GCT ACA ATA (nucleotides 415-436) .
32P-5'-endlabeling and Southern hybridization techniques followed
standard protocols (13) . Labeled oligonucleotide was separated from
unincorporated y-[32p]ATPby passage over NucTrap push columns
(Stratagene Inc., LaJolla, CA). -30ACi ofprobe (specific activity
of 0.7 p,Ci/pm) was used in Southern hybridization after vacuum
transfer ofagarose gels to Nytran membranes (Schleicher &Schuell,
Inc., Keene, NH) following recommended protocols (Pharmacia-
LKB, Uppsala, Sweden) . Unless otherwise indicated, gels were au-
toradiographed for 3 d at -80° with Kodak X-GMAT film
(Eastman Kodak Co., Rochester, NY) and DuPont Cronex inten-
sifying screens (DuPont Instruments, Wilmington, DE) .
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Tissue Preparation for PCR Analysis .
￿
1 g of lung tissue (wet
weight) wasadded to 25 ml of PBSand homogenizedcompletely
in ahomogenizer (PolytronFT3000; Brinkmann, Littau, Switzer-
land) . The sample was centrifuged at 2,000g for 10 min and the
supernatant discarded . The pellet wasthen rinsed twiceby adding
PBS and centrifuging as above. Pelleted material was resuspended
in 20 ml ofbuffer containing 10 mM Tris (pH8.0), 20 mM EDTA,
and 140mM NaCl . 1 ml of 10% SDS was then added, followed
by 2 mg of fresh proteinase K. The solution was digested over-
night at 37°. The next day, the solution was extracted with
phenol/chloroform, dialyzed against buffer containing 10mM Tris
(pH 8.0) and 1mM EDTA, and precipitated andwashed with eth-
anol . 150 ng of totalDNA was used as template for PCR. To de-
termine the yield ofP . cariniiDNA extracted from homogenized
lung tissue, purified P . cariniiDNA (1-100 pg) was added to con-
trol lung homogenate (P . cariniiDNAnegative by PCR), extracted,
and amplified as described above.A5-10-fold loss inP . cariniiDNA
template was observed to result from lung tissue extraction .
Human bronchoalveolar lavage (BAL) fluid was obtained from
patients undergoing diagnostic evaluation for pulmonary disease.
2 ml of bronchoalveolar lavage fluid was centrifuged at 15,000g
for 10 min . The supernatant was discarded and the pellet was
resuspended in 0.5 ml of buffer containing 10 mM Tris (pH 8.0)
and 1 mM EDTA and recentrifuged . The supernatant was aspi-
rated and 50 P,1 ofH2O was added to the pellet . This mixturewas
heated to 95° for 5 min . 5 gl was used for DNA amplification .
To determine the yield ofP . cariniiDNA extractedfromBAL speci-
mens, purified P . carinii DNA (1-100 pg) was added toBAL pellets
obtained after centrifugation of control BAL specimens (P . carinii
DNA negative). Samples were then extracted and amplified as de-
scribed above. The purification and extraction ofDNA fromBAL
specimens was observed to result in a 5-10-fold loss in the ability
to detect the DHFR template.
Whole blood samples were obtained from both uninfected rats
(n = 20) and P . carinii-infected rats (n = 18) . To minimize the
possibility that blood couldbe contaminated with lung tissue con-
taining P . carinii, blood was drawn in two ways. For rats under-
going serial blood samples, tail vein blood was obtained . For rats
that were used both for analysis of lung tissue and blood, rats were
sacrificed by C02 . The chest cavity was opened immediately and
blood samples obtained by cardiac puncture under direct visualiza-
tion so that lung tissue was not disturbed during sampling. Human
blood was obtained from healthy laboratory workers (n = 9), pa-
tients with AIDS and clinically active P . carinii pneumonia (n =
14), and patients with advanced AIDS (CD4 lymphocyte count
<50 per mm'), but without prior history ofP . carinii pneumonia
(n = 6) . The diagnosis ofP . carinii pneumonia was confirmed by
microscopic examination ofinduced sputum or bronchoalveolar la-
vage fluid . The patients with AIDS andno history ofP . carinii pneu-
moniawere followed clinically for at least 3 mo after serum collec-
tion andcontinued to have no evidence ofP . carinii infection. Care
was taken to ensure that serum was prepared expeditiously and
stored frozen . DNA amplification analysis was performed in the
following manner. To 20 Al ofserumwas added 25 P1 of a solution
of 10mM Tris (pH8.0), 5mM EDTA, 0.25% SDS, and0.25 mg/ml
proteinaseK. This preparation was incubated for 2 h at 56° and
then heated to 95° for 10 min to inactivate protease . 45 Al ofbuffer
containing 100mM Tris (pH 8.3), 500mM KCI, 25 MM MgC12 ,
and 1% Tween 20 then was added . 5 pl were utilized forDNA
amplification . Buffy coats also wereprepared from thewholeblood
of infected rats and digested with proteinaseK andSDS as above
before PCR analysis. Several positive sera were filtered through
0.22 Fc micropore filters (Spin-X; Costar Corp., Cambridge, MA)or subjected to DNAse treatment before DNAamplification . For
DNAse treatment,PCRpositive serum (401.1) wasincubated with
0.4UDNAse I (after addition of 1:10volume ofbuffer containing
500mM Tris [pH 7.5] and 100MM MgCl 2) for 2 h at 37°. These
conditions were sufficient to eliminate completely the template ac-
tivity of 100pg ofP . cariniiDNAwhich hadbeen added to control
serum beforehand. Treated serum was then incubated with pro-
teinaseK and SDS as described above, heated to 95° for 10 min
to inactivate enzymes, and subjected to DNA amplification . To con-
trol for the possible carryover ofDNAse into the PCR reaction,
100 pg of genomicP . cariniiDNA was added to control (P . carinii
DNA negative) serum after DNAse treatment and heat inactiva-
tion . Amplification of this sample wasfound to producePCRprod-
ucts of the same intensity as samples without DNAse treatment .
Sera also were examined forP . carinii by methenamine-silver staining
and immunohistochemistry 3F6 monoclonal anti-P . carinii antibody.
For these studies, 0.1 ml of serumwas concentrated onto glass slides
by cytospin .
Results
A 273 by portion of the DHFR gene which was 3' to
the intron was selected forDNA amplification . PCR condi-
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tions were tested empirically and optimized to attain max-
imum sensitivity. Amplification ofP . cariniiDNA with the
DHFR primers was found to yield a singleDNA band of
a size consistent with that predicted for the273-bp gene seg-
ment enclosed by the primer sequences . Cleavage of the
amplifiedband with the restriction enzymesSnoI andFnu4H1
resulted in DNA fragments which corresponded in size to
those predicted by the position of these restriction sites within
the amplified region . Amplification of genomicDNA from
representative gram-negative (Escherichia colt) and gram-positive
(Streptococcus pyogenes) bacteria, as well as the fungus Can-
dida albicans, didnot yield detectablePCRproducts (datanot
shown) .
To establish the utility of P . carinii DHFR DNA am-
plification in pneumocystosis, we first studied the cortico-
steroid-treated rat, an experimental model ofP . carinii pneu-
monia (5, 9) . At intervals, animals were killed and whole
lung tissue was processed forDNA amplification. At 4 wk
ofcorticosteroid treatment, rats developed pulmonary pneu-
mocystosis as determined both by characteristic histopatho-
logical changes (foamy, eosinophilic alveolar exudates) and
by direct visualization ofP . carinii. Fig . 1 shows the results
Figure 1.
￿
DNA amplification analysis of rat lungs .
(Top) Ethidium bromide stained gel ofPCR products
obtained afterDNAamplification of indicated samples .
(123 bp) Multimeric DNA standards. (STDs) 10 pl of
DNAproducts obtained after amplification of purified
P . carinii genomicDNA (lanes a-d) . (Control) Results
obtained from analysis of three representative control,
untreated rats which were housed separately from the
corticosteroid-treated group (out of five studied) (lanes
e-g) . (Corticosteroid- treated) PCR analysis of lungs ob-
tained from 11 rats after the indicated duration ofcorti-
costeroid treatment (lanes h-r) . (Bottom) Southern hy-
bridization of same gel with 32P-labeled oligonucleotide
probe . Exposure was for three d at -H0° with Kodak
X-OMAT film and an intensifying screen .ofDHFRDNA amplification ofDNA isolated from whole
lung tissue in control and corticosteroid-treated rats . Ethidium
bromide staining clearly demonstrated an amplifiedDNA band
of predicted size in lung homogenates that were analyzed
at 6 wk of corticosteroid treatment . Southern hybridization
of this gel (with a 31P-labeled internal oligonucleotide probe)
confirmed that the amplified product was P . carinii DHFR
DNA . Inspection of the intensities of P . carinii DNA stan-
dards showed that after three days of autoradiography, the
combination ofDNA amplification with Southern hybrid-
ization produced a 100-fold greater sensitivity in detection
than didDNA amplification alone . After 6 d of autoradiog-
raphy, faint signals specific for P . carinii DHFRDNA were
visualized as early as 2 wk after the initiation of corticoste-
roid treatment . Under these conditions, as little as 10 fg of
P . carinii DNA generally could be detected . Assuming a
minimum haploid genome size of 7,000 kb (14), this would
correspond approximately to one organism . Neither histo-
pathological changes, nor direct visualization of organisms
by GramWiegert, methenamine silver, or immunoperoxi-
dase stains with 3F6 mAb suggested the presence of active
infection at this time. Lungs obtained from five control rats
(untreated and housed separately) were negative when ana-
lyzed byDNA amplification and Southern hybridization . The
addition of known quantities ofP . carinii DNA (1-100 pg)
to control, PCR-negative lung homogenates resulted in a
5-10-fold loss in P . carinii DNA after amplifications of ex-
tracted material .
We next appliedDHFRDNA amplification to an analysis
of other biological samples . Serum samples from rats with
pulmonary pneumocystosis were amplified and analyzed by
gel electrophoresis and Southern hybridization . Fig. 2 shows
the results obtained from nine representative animals which
Figure 2 .
￿
Gel electrophoresis and Southern hybridization ofPCR prod-
ucts from serum obtained from rats with experimentally-induced P . carinii
pneumonia . Animals are from the same group shown in Fig. 1 . (STD)
P . carinii genomic DNA (lanes a-cl) . (A) PCR analysis of control serum
to which 0 .1 pg of P . carinii DNA was added after (lane e) and before
(lanef) filtration through a 0.221 micropore filter (Spin-X ; Costar, Cam-
bridge, MA) . (B) PCR analysis of a positive rat serum (10wk of cortico-
steroid treatment) after (laneg) and before(lane h) serum filtration through
a 0.22 1 micropore filter. PCR analysis of sera obtained from nine rats
after the indicated duration of corticosteroid treatment (lanes i-q) .
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were killed at the indicated times. Sera from three animals,
two at 10 wk of corticosteroid treatment, and one at 6 wk
of treatment, demonstrated DHFR DNA at levels which
ranged from 0 .1 to 1 pg per /.1 of serum . In a second series
ofanimals, amplifiedDHFRDNA signals were observed to
be present in the serum of all 10 rats whose blood was sam-
pled from tail veins at 8, 9, and 10wk ofcorticosteroid treat-
ment . Blood specimens sampled at 2 and 4 wk were uni-
formly negative (0/10) . Control, untreated rats showed no
detectable levels of serum DHFRDNA (n = 20, age range
3-16 mo) . Analysis of whole blood or buffy coats obtained
fromP . carinii-infected rats also showed positiveDHFRDNA
signals. The PCR signals obtained from these specimens, how-
ever, showed greater variability than those obtained from
serum . This appeared to be due to variable yields ofP . carinii
DNA obtained from extracted blood cells, as well as the pres-
ence of substances that interfered with theDNA amplification
reaction (data not shown) .
Because of the exact sequence homology between the rat
and the human-derived P . carinii DHFR gene (8), we rea-
soned that theDHFR amplification assay might readily de-
tect P . carinii in human specimens . Fig . 3 shows the PCR
analysis of 11 bronchoalveolar lavage fluid samples obtained
from patients who underwent fiberoptic bronchoscopy for
a variety of clinical indications . P . carinii DHFRDNA was
readily demonstrated in samples obtained from three patients
with histopathologically proven P . carinii pneumonia . It was
not detected in samples obtained from eight patients without
pneumocystosis .
We next examined patient sera for the presence ofP . carinii
DHFRDNA . Fig . 4 shows a representative autoradiograph
of this analysis and Table 1 summarizes the results obtained
from different patient groups . The initial application of this
Figure 3 .
￿
DNA amplification analysis of human bronchoalveolar lavage
fluid samples . (-PCP) Lavage fluid obtained from eight patients without
P . carinii pneumonia (lanes a-h) . (+PCP) Lavage fluid obtained from three
patients with confirmed P . carinii pneumonia (lanes i-k) . (STDs) DNA
amplification of P . carinii genomic DNA (lanes 1 and m) .assay to previously stored sera obtained from patients with
P . carinii pneumonia revealed evidence ofP . cariniiDNA in
two of six samples. We then collected 14 samples prospec-
tively from acutely infected patients and processed the sera
in a standardized fashion . Serum samples were collected within
48 h of diagnosis and the majority were drawn at the time
of initial clinical presentation, before the start of therapy, and
before any invasive diagnostic procedure . Of these specimens,
12 of 14 (86%) were observed to haveP . cariniiDHFRDNA
as detected by PCR . Sera from six patients with advanced
AIDS (CD4 lymphocyte count <50 mm3), but without a
history ofP . carinii pneumonia were negative by this assay .
Sera obtained from nine healthy laboratory workers also
showed no evidence ofP . carinii DNA . Based on theP . carinii
DNA standard dilution curve (lanes o-q) and the recovery
ofP . cariniiDNA after serum extraction (lane m), we esti-
mate that positive sera contained from 5-25 DHFR templates
per p1 .
To investigate the physical nature of serum DHFR DNA,
serum from experimentally infected rats (Fig. 2 B, lanes g
and h) and humans (Fig . 4, lane 1) was filtered through a
0.22,u filter and the filtrate amplified by PCR . This resulted
in a disappearance of the DHFR band, suggesting that cel-
lular or particulate material was the source of the P . carinii
template DNA . When P . carinii DNA was added to control
serum, filtration did not affect the ability ofDNA ampli-
Table 1 .
￿
Summary ofDNA Amplification Analysis of
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Figure 4 .
￿
Representative DNA amplification analysis
ofhuman sera . Sera frompatients with AIDS but without
a history ofP . carinii pneumonia (lanes a-e), and patients
with AIDS and acuteP . cariniipneumonia (lanes_f-k). DNA
amplification of lane k specimen after filtration through
a 0.22 A micropore filter (lane h . PCR analysis of control
(PCR negative) human serum to which 0 .1 pg ofP . carinii
DNA was added before filtration through a 0.221 micro-
pore filter (lane m) . PCR analysis oflane k specimen after
treatment with DNAse I (lane n) . DNA amplification of
control serum which had been treated with DNAse, pro-
teinase K, and heat inactivation, followed by the addition
ofP . cariniiDNA (0.1 pg), producedDHFRDNA prod-
ucts equivalent to lane o, indicating that DNAse did not
carry over into the amplification reaction (not shown) .
fication to detect it, indicating that P . cariniiDNA had not
been removed by nonspecific binding to the micropore filter
(Fig. 2 A, lanes e andf ) . Although these experiments sug-
gest that whole parasites might be the source ofDHFR tem-
plate, direct microscopic examination of serum (100 p.l) or
whole blood (10 ul) by either methenamine silver staining
or immunohistochemistry with anti-P . carinii mAb revealed
no demonstrable organisms . To further address the nature
of serum DHFR template, PCR positive patient sera were
incubated with DNAse under conditions in which ex-
ogenously added P . carinii DNA is completely hydrolyzed .
As shown in Fig. 4,DNAse digestion completely eliminated
the PCR positive signal present in patient sera . Taken to-
gether, these results suggest that the serum DHFR template
is associated with filterable material that is sensitive toDNAse.
Template DNA may represent damaged organisms that are
sensitive to DNAse or high-molecular weight, protein-DNA
aggregates released from phagocytic cells.
Discussion
P . carinii pneumonia is a leading cause of morbidity and
mortality among patients with AIDS (1, 2) . The lack ofreli-
able cultivation methods has hampered investigations into
the basic biology and epidemiology ofP . carinii and the diag-
nosis of infection relies solely on the direct visualization of
organisms in respiratory secretions or lung biopsy material
(3, 5) .
DNA amplification of the DHFR gene ofP . carinii offers
a highly sensitive and specific technique for the detection of
P . carinii. Recent studies utilizing primers forP . carinii ribosomal
RNA genes have demonstrated the utility of this technique
in increasing the sensitivity of the detection of P . carinii in
bronchoalveolar lavage fluid (7) . For our studies, we selected
to amplify the P carinii DHFR gene . This gene has no se-
quence homology with any known prokaryotic or eukary-
otic DHFR genes (8) . DNA amplification of crude lung
homogenates known to containP . carinii resulted in a single
DNA product of predicted size . Sequence identity with
authenticDHFR DNA was confirmed by restriction enzyme
mapping and Southern hybridization with internal oligonu-
Human Serum for P. carinii DHFR DNA
Patient Category
Positive sera/
Total sera
AIDS, active P. carinii 12/14
pneumonia
Advanced AIDS, no history 0/6
of P. carinii pneumonia
Normal controls 0/9cleotide probe . By combining DNA amplification with
Southern hybridization, as little as 10 fg of genomic P . carinii
DNA was detected, an amount corresponding, on average,
to one P . carinii haploid genome.
The utility of this assay was confirmed in the corticosteroid-
treated rat model of pneurnocystosis and allowed for the de-
tection of P . cariniiDNA in infected rat lungs 2 wk before
the onset of histological changes . DNA amplification anal-
ysis of lung tissue obtained from control, untreated rats showed
no evidence ofP . cariniiDNA. Based on our DNA yield and
standard dilution curves for DHFRDNA amplification, we
estimate that the control (uninfected) rat lung contains <3,000
organisms per gram of lung tissue (wet weight) . Although
P . carinii pneumonia generally is considered to result from
the reactivation of a latent infection, this analysis of rat lung
suggests that the carriage of organisms is low. Serum anal-
ysis revealed that by 10 wk of treatment, 12 of 12 (100%)
ofcorticosteroid-treated rats demonstratedP . cariniiDNA in
their serum, representing ti2-25 templates per P,1 .
The PCR assay for P . cariniiDHFRDNA is equally ap-
plicable to human pneurnocystosis and detectsP . carinii both
in bronchoalveolar lavage fluid and in the serum of AIDS
patients with activeP . carinii pneumonia . In the sera analyzed
for this study, there appears to be a high correlation between
activeP . cariniipneumonia and the presence ofP . carinii DNA
in the serum (12 of 14 specimens analyzed) . In six patients
with advanced AIDS, but without a history ofP . carinii pneu-
monia, no positive PCR signals could be detected . These
results present the possibility that serum PCR for P . carinii
maybe useful as a diagnostic procedure in some patients with
suspectedP . carinii infection . This would be ofparticular value
because current diagnosis ofP . carinii pneumonia frequently
requires an invasive procedure such as bronchoscopy to ob-
tain respiratory specimens for direct microscopic examina-
tion . We have yet to determine how long the serum DHFR
DNA signal persists in infected patients . Examination ofserial
serum specimens, however, may offer prognostic information
about the severity of infection and parasite burden, as well
as efficacy of antibiotic prophylaxis and treatment .
The precise nature of theP . cariniiDNA which is detected
by PCR has not been elucidated in the present study. Al-
though the DHFR template could be removed by serum filtra-
tion through a 0.22 p filter, efforts to demonstrate intact or-
ganisms in serum by histochemical or immunostaining were
unsuccessful. Treatment ofP . cariniiDNApositive serum with
DNAse resulted in a loss ofPCR signal, suggesting that the
serum DHFR template consists of either free DNA or or-
ganisms that had been rendered sensitive to DNAse treat-
ment . It is possible that P . carinii template represents high
molecular weight DNA complexes originating from para-
sitesdamaged by phagocytosis or serum storage. The reported
occurrence ofextrapulmonary pneurnocystosis (15), however,
suggests that in some patients, P . carinii may have a blood-
borne phase . Evidence byDNA amplification that P . carinii
may be blood-borne offers important information about the
natural history of this infection and would readily explain
the pathogenesis of extrapulmonary pneumorystosis .
An important, unresolved question in the pathophysiol-
ogy of pneumocystosis concerns the transmissibility of this
infection . For example, it has been noted that at an early
age a majority of individuals possess serological evidence of
P . carinii infection (16, 17) . This has lent support to the con-
cept that clinical pneurnocystosis results from the reactiva-
tion of latent infection (3, 5, 17), as occurs in other infec-
tions associated with T cell immunodeficiency such as
tuberculosis, histoplasmosis, and cryptococcosis . Alternatively,
the occurrence ofP . carinii point epidemics (18, 19), as well
as the failure to demonstrate organisms in autopsy studies,
suggests that the asymptomatic carriage ofP . carinii in fact
may be quite low (20, 21) . DNA amplification analysis of
serum, sputum, bronchoalveolar lavage fluid, and autopsied
lung tissue may help to clarify this central issue concerning
P . carinii infection (22) . Better insight into the pathophysi-
ology and epidemiology ofthis infection will offer more effec-
tive strategies in preventing this frequently fatal opportunistic
infection .
We are grateful to Drs. Urs Widmer and Annette Lee for helpful suggestions . We thank Linda Rourke
and Steven Balint for technical assistance .
This study was supported in part by the Stony Wold-Herbert Fund Foundation (N . Schluger), National
Institute of Allergy and Infectious Diseases grant 5 U01 AI27669-04 (K. Septowitz, D . Armstrong,
and E. Bernard), and grants from the American Foundation for AIDS Research (AmFAR) (R . Bucala
and M . Rifkin) .
Address correspondence to Richard Bucala, The Picower Institute for Medical Research, 350 Community
Drive, Manhasset, NY 11030 .
Received for publication 7 April 1992 and in revisedform 24 July 1992.
1332
￿
Serum Polymerase Chain Reaction ofP . cariniiReferences
1 . Selik, R.M ., ET Starcher, and J.W . Curran . 1987 . Oppor-
tunistic diseases reported inAIDS patients : frequencies, associ-
ations and trends. AIDS (Phila .) . 1:175 .
2 . Centers for Disease Control . Guidelines for prophylaxis against
Pneumocystis carinii pneumonia in patients infected with the
humanimmunodeficiency virus . 1989 . Morbidity and Mortality
Weekly Report 38(8):1 .
3 . Masur, H., H.C . Lane, J.A . Kovacs, C.J . Allegra, and J.C .
Edman . 1989 . Pneumocystis pneumonia: from bench to clinic .
Ann. Intern. Med . 111:813 .
4. Walzer, P.D., R.D . Powell, K. Yoneda, M.E . Rutledge, and
J.E . Miller. 1980 . Growth characteristics andpathogenesis of
experimental Pneumocystis carinii pneumonia . Infect . Immun.
27:928 .
5 . Hughes, W.T . 1987 . Pneumocystis carinii Pneumonitis. CRC
Press, Inc. Boca Raton-
6 . Saiki, R.K.,D.H . Gelfand, S . Stoffel, S.J . Scharf,R. Higuchi,
G.T. Horn,K.B. Mullis,andH.A . Erlich. 1988 . Primer-directed
enzymatic amplification ofDNA with a thermostable DNA
polymerase. Science (Wash . DC) . 239:487 .
7 . Wakefield, A.E ., L . Guiver, R.F . Miller, and J.M . Hopkin .
1991 . DNA-amplification in induced sputum samples for di-
agnosis of Pneumocystis cariniipneumonia. Lancet (N. Am .Ed.).
337:1378 .
8 . Edman, J.C ., U. Edman, B . Lundgren, J.A . Kovacs, andD.V.
Santi . 1989 . Isolation and expression and Pneumocystis carinii
dihydrofolate reductase gene . Proc. Natl. Acad. Sci. USA. 86 :
8625.
9 . Frenkel, J.K ., J.T. Good, andJ.A . Schultz . 1966 . Latent Pneu-
mocystis infection of rats, relapse and chemotherapy. Lab . In-
vest. 15:1559 .
10 . Radio, S.J ., S . Hansen, J. Goldsmith, and J . Linder. 1990. Im-
munohistochemistry of Pneumocystis carinii infection . Mod .
Pathol . 3:462 .
11 . Armstrong,MYK., andF.F. Richards . 1990 . Propagationand
1333
￿
Schluger et al .
purification of rat Pneumocystis carinii in short-term cell cul-
ture. J . Protozool. 365:24 .
12 . Erlich,H.A . 1989 . PCR Technology: Principles and Applica-
tions forDNAAmplification . Stockton Press, NewYork . 7-16 .
13 . Maniatis, T ., F.F. Fritsch, andJ . Sambrook . 1982 . Molecular
Cloning : ALaboratory Manual, Cold Spring Harbor Labora-
tory, Cold Spring Harbor, NY 382-389 .
14 . Lundgren, B., R. Cotton, J.D . Lundgren, J.C . Edman, and
J.A . Kovacs . 1990 . Identification of Pneumocystis carinii chro-
mosomes and mapping of five genes. Infect. Immun. 58:1705.
15 . Telzak, E.E ., R.J . Cote,J .W .M .Gold, S.W. Campbell, and
D . Armstrong. 1990 . Extrapulmonary Pneumocystis carinii in-
fections. Rev . Infect. Dis. 12:380 .
16 . Pifer,L.L .,WT Hughes, S . Stagno, andD. Woods . 1978 . Pneu-
mocystis carinii infection: Evidence for high prevalence in normal
and immunosuppressed children . Pediatrics. 136 :43 .
17 . Peglow, S.L ., A.G. Smulian,M.J. Linke, C.L . Pogue, S. Nurre,
J . Crisler, J . Phair, J.W.M . Gold, D . Armstrong, and P.D.
Walzer. 1990 . Serologic responses to Pneumocystis carinii an-
tigens in health and disease. J . Infect. Dis. 161:296 .
18 . Singer, C., D . Armstrong, P.P. Rosen, and D. Schottenfeld.
1975 . Pneumocystis cariniipneumonia : a cluster of eleven cases.
Ann. Intern . Med . 82:772 .
19 . Chusid,M.J ., andK.A . Heyrman . 1978 .An outbreak ofPneu-
mocystis carinii pneumonia at a pediatric hospital . Pediatrics .
62:1031.
20 . Sheldon,W.H . 1959 . SubclinicalPneumocystis pneumonitis.Am .
J . Dis . Child. 97:287.
21 . Millard, P.R., andA.R . Heryet . 1988 . Observation s favoring
Pneumocystis cariniipneumonia as aprimary infection : a mono-
clonal antibody study on paraffin sections.J . Pathol. 154:365 .
22 . Peters, S.E ., A.E . Wakefield,K . Sinclair, P.R . Millard, and J.M .
Hopkin . 1992 . A search forPneumocystis carinii in post-mortem
lungs by DNA amplification.J . Pathol. 166:195 .